{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:43:28Z","timestamp":1784861008108,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.eprac.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T19:51:51Z","timestamp":1670615511000},"page":"408-413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Managing Bone Health in Breast Cancer"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4886-3027","authenticated-orcid":false,"given":"Ann E.","family":"Kearns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2022.12.003_bib1","first-page":"298","article-title":"Post-menopausal osteoporosis","volume":"55","author":"Albright","year":"1940","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1016\/j.eprac.2022.12.003_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","author":"Eastell","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.eprac.2022.12.003_bib3","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1210\/jc.2005-0396","article-title":"Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women","volume":"90","author":"Khosla","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2022.12.003_bib4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group","volume":"339","author":"Cummings","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.12.003_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ecl.2013.02.003","article-title":"Endogenous sex steroid levels and cardiovascular disease in relation to the menopause: a systematic review","volume":"42","author":"Crandall","year":"2013","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"10.1016\/j.eprac.2022.12.003_bib6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/PPO.0000000000000596","article-title":"Mechanistic effects of estrogens on breast cancer","volume":"28","author":"Santen","year":"2022","journal-title":"Cancer J"},{"key":"10.1016\/j.eprac.2022.12.003_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920925991","article-title":"Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study","volume":"12","author":"Wang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.eprac.2022.12.003_bib8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fphar.2017.00620","article-title":"Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation","volume":"8","author":"Quirke","year":"2017","journal-title":"Front Pharmacol"},{"issue":"suppl 7","key":"10.1016\/j.eprac.2022.12.003_bib9","doi-asserted-by":"crossref","first-page":"vii10","DOI":"10.1093\/annonc\/mdl941","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial","volume":"17","author":"Boccardo","year":"2006","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.eprac.2022.12.003_bib10","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.ejca.2012.12.025","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial","volume":"49","author":"Boccardo","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9453","key":"10.1016\/j.eprac.2022.12.003_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eprac.2022.12.003_bib12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.eprac.2022.12.003_bib13","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A\u00a0comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Th\u00fcrlimann","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.12.003_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.eprac.2022.12.003_bib15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMoa0810818","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer","volume":"361","author":"Mouridsen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.eprac.2022.12.003_bib16","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2006.08.8054","article-title":"Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study","volume":"25","author":"Kaufmann","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9484","key":"10.1016\/j.eprac.2022.12.003_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eprac.2022.12.003_bib18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1200\/JCO.2011.36.8993","article-title":"Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group","volume":"30","author":"Dubsky","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"9561","key":"10.1016\/j.eprac.2022.12.003_bib19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.eprac.2022.12.003_bib20","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1200\/JCO.2016.70.5640","article-title":"Long-term follow-up of the Intergroup Exemestane study","volume":"35","author":"Morden","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"9762","key":"10.1016\/j.eprac.2022.12.003_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial","volume":"377","author":"van de Velde","year":"2011","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.eprac.2022.12.003_bib22","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.eprac.2022.12.003_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.886954","article-title":"Efficacy and safety of initial 5 years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: a systematic review and network meta-analysis","volume":"13","author":"Liao","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.eprac.2022.12.003_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1759720X18759291","article-title":"Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis","volume":"10","author":"Tseng","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7","key":"10.1016\/j.eprac.2022.12.003_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.eprac.2022.12.003_bib26","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2022.12.003_bib27","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1470-2045(14)70035-X","article-title":"Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial","volume":"15","author":"Goss","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2022.12.003_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1470-2045(18)30116-5","article-title":"Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial","volume":"19","author":"De Placido","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2022.12.003_bib29","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.eprac.2022.12.003_bib30","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2022.12.003_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2022.12.003_bib32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2022.12.003_bib33","first-page":"145","article-title":"Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: the BATMAN trial","volume":"2","author":"Lomax","year":"2013","journal-title":"J\u00a0Bone Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2022.12.003_bib34","first-page":"57","article-title":"Prevention of anastrozole induced bone loss with monthly oral ibandronate: final 5 year results from the ARIBON trial","volume":"1","author":"Lester","year":"2012","journal-title":"J\u00a0Bone Oncol"},{"issue":"6","key":"10.1016\/j.eprac.2022.12.003_bib35","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2022.12.003_bib36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.eprac.2022.12.003_bib37","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2022.12.003_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","article-title":"Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial","volume":"12","author":"Llombart","year":"2012","journal-title":"Clin Breast Cancer"},{"issue":"30","key":"10.1016\/j.eprac.2022.12.003_bib39","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9992","key":"10.1016\/j.eprac.2022.12.003_bib40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2022.12.003_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.eprac.2022.12.003_bib42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.eprac.2022.12.003_bib43","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/annonc\/mdr600","article-title":"Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study","volume":"23","author":"Nuzzo","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eprac.2022.12.003_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bone.2018.06.007","article-title":"Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial","volume":"114","author":"Kyvernitakis","year":"2018","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.eprac.2022.12.003_bib45","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.21.02647","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update","volume":"40","author":"Eisen","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"10001","key":"10.1016\/j.eprac.2022.12.003_bib46","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.eprac.2022.12.003_bib47","doi-asserted-by":"crossref","first-page":"19835","DOI":"10.18632\/aging.203395","article-title":"Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies","volume":"13","author":"Liu","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"10","key":"10.1016\/j.eprac.2022.12.003_bib48","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2014.3634","article-title":"Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid","volume":"174","author":"Hue","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.12.003_bib49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.eprac.2022.12.003_bib50","doi-asserted-by":"crossref","first-page":"M599","DOI":"10.1093\/gerona\/57.9.M599","article-title":"Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data","volume":"57","author":"Kelley","year":"2002","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.eprac.2022.12.003_bib51","first-page":"1","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J\u00a0Bone Oncol"},{"issue":"suppl 3","key":"10.1016\/j.eprac.2022.12.003_bib52","first-page":"S1","article-title":"NCCN Task Force Report: bone health in cancer care","volume":"7","author":"Gralow","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"31","key":"10.1016\/j.eprac.2022.12.003_bib53","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eprac.2022.12.003_bib54","article-title":"Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer","volume":"28","author":"Waqas","year":"2021","journal-title":"J\u00a0Bone Oncol"},{"key":"10.1016\/j.eprac.2022.12.003_bib55","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.12.003_bib56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2022.12.003_bib57","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2018.09.010","article-title":"Bone health evaluation one year after aromatase inhibitors completion","volume":"117","author":"Pineda-Moncus\u00ed","year":"2018","journal-title":"Bone"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22008783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22008783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:14:09Z","timestamp":1761516849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22008783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1530891X22008783"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.12.003","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Bone Health in Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}